A Phase 2 interventional study of RESP301 and HRZE in Rifampicin Susceptible Pulmonary Tuberculosis, sponsored by Thirty Respiratory Limited. Terminated at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Thirty Respiratory Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing isoniazid in Tuberculosis, Pulmonary — 1 open to participants now, 2 under way, none of them phase 3. Isoniazid · Tuberculosis, Pulmonary.
Among the 14 studies testing isoniazid in Tuberculosis, Pulmonary, this one is the 14th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 2, and was the 13th registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →1 of the 14 studies testing isoniazid in Tuberculosis, Pulmonary is open now, in 6 countries. Recruiting first, the newest first:
Michael Hoelscher · Sites in Gabon, Malawi, Mozambique and 3 more countries
Ages 18–65
By country, each count listing its studies:
Isoniazid: first FDA approval 1952 (NYDRAZID). What it is approved for, and how studies give it, is on its page →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2023.
This study's enrollment of 20 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 229 across the 14 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Thirty Respiratory Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Thirty Respiratory Limited has 2 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
1 of the studies testing isoniazid in Tuberculosis, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing isoniazid in Tuberculosis, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 2, Single-Centre, Open-Label, Parallel Control Arm, Randomised Clinical Study to Evaluate the Early Bactericidal Activity (EBA), Safety and Tolerability of Nebulised RESP301 in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
A total of approximately 15 participants will be recruited per treatment arm (total of approximately 75 participants in the study). Control arm participants will be split across sequential stages stages 1 and 2, with no stratification.
Stage 1: To determine the EBA of
On completion of Stage 1, recruitment will be paused and an interim analysis performed to determine whether the study should proceed to Stage 2.
Stage 2: To determine the EBA of
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled RESP301 6ml via nebulisation three times daily
Drug: RESP301
HRZE taken orally once daily
Drug: HRZE
Inhaled RESP301 6 ml via nebulisation once daily
Drug: RESP301
Inhaled RESP301 6 ml via nebulisation twice daily
Drug: RESP301
Inhaled RESP301 6 ml via nebulisation three times daily plus HRZE taken orally once dialy
Drug: RESP301 · Drug: HRZE
Nitric Oxide agent
Drug pages: Isoniazid · Rifampin · Pyrazinamide · Ethambutol
isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Time to Positivity (TTP)
Overnight sputum collection from which viable mycobacteria in the sample is quantified as TTP Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in TTP (hours) for treatment in each of the treatment groups
Time frame: 0-2, 0-7, 0-14, 0-15 and 14-15 days
Early Bactericidal Activity (EBA) of Inhaled RESP301 Measured as Colony Forming Units (CFU)
Overnight sputum collection from which viable mycobacteria in the sample is quantified as CFU Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in CFU (Log10 CFU/mL) for treatment in each of the treatment groups
Time frame: 0-2, 0-7, 0-14, 0-15 and 14-15 days
Safety and Tolerability of Inhaled RESP301 Measured as Number of Treatment Emergent Adverse Events (TEAEs)
Incidence of Treatment Emergent Adverse Events (TEAEs) will be presented by severity, drug relatedness, seriousness, leading to early withdrawal and leading to death.
Time frame: Stage 1: Dosing period 14 days + Follow-up period 14 days. Stage 2: Participants did not enter the treatment phase due to early study termination
| Milestone | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) |
|---|---|---|---|---|---|
| Started | 15 | 5 | 0 | 0 | 0 |
| Completed | 14 | 4 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: At the request of the investigator or the sponsor | 0 | 1 | 0 | 0 | 0 |
Overnight sputum collection from which viable mycobacteria in the sample is quantified as TTP Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in TTP (hours) for treatment in each of the treatment groups
| Hours | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) |
|---|---|---|---|---|---|
| 0-2 | 3.5 (-5.2 to 5.6) | 63.5 (53.2 to 78.2) | — | — | — |
| 0-7 | 2 (-6.9 to 15) | 140.2 (117 to 160) | — | — | — |
| 0-14 | 2.5 (-7.8 to 9.1) | 167.8 (147.8 to 200.5) | — | — | — |
| 0-15 | 6.2 (-8 to 16.1) | 225 (157.8 to 247.5) | — | — | — |
| 14-15 | 7.5 (-3 to 17.5) | 2 (-5 to 47) | — | — | — |
Overnight sputum collection from which viable mycobacteria in the sample is quantified as CFU Observed EBA for 0-2, 0-7, 0-14, 0-15 and 14-15 days in CFU (Log10 CFU/mL) for treatment in each of the treatment groups
| Log10 CFU/mL | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) |
|---|---|---|---|---|---|
| 0-2 | 0.3 (-0.1 to 0.5) | -0.9 (-0.9 to -0.6) | — | — | — |
| 0-7 | 0.2 (-0.2 to 0.4) | -1.2 (-1.6 to -0.8) | — | — | — |
| 0-14 | 0.4 (-0.2 to 0.8) | -2.9 (-3.1 to -2.7) | — | — | — |
| 0-15 | 0.3 (-0.4 to 0.7) | -2.4 (-3.6 to -1.4) | — | — | — |
| 14-15 | 0 (-0.3 to 0.1) | 0.1 (0.1 to 0.1) | — | — | — |
Incidence of Treatment Emergent Adverse Events (TEAEs) will be presented by severity, drug relatedness, seriousness, leading to early withdrawal and leading to death.
| events | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) |
|---|---|---|---|---|---|
| Number of Grade 1 (Mild) TEAEs | 38 | 7 | — | — | — |
| Number of Grade 2 (Moderate) TEAEs | 13 | 2 | — | — | — |
| Number of Grade 3 (Severe) TEAEs | 2 | 0 | — | — | — |
| Number of Grade 4 (Life-threatening) TEAEs | 0 | 0 | — | — | — |
| Number of Unrelated TEAEs | 27 | 8 | — | — | — |
| Number of Related TEAEs | 26 | 1 | — | — | — |
Collected over Stage 1: Dosing period 14 days + Follow-up period 14 days. Stage 2: Participants did not enter the treatment phase due to early study termination. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 (Active) | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| 2 (Control) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| 3 (Active) | — | — | — |
| 4 (Active) | — | — | — |
| 5 (Active) | — | — | — |
| Event | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 13/15 | 0/5 | — | — | — |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 6/15 | 0/5 | — | — | — |
| Abdominal PainGastrointestinal disorders | 2/15 | 1/5 | — | — | — |
| Vulvovaginal CandidiasisInfections and infestations | 1/15 | 1/5 | — | — | — |
| Otitis MediaInfections and infestations | 0/15 | 1/5 | — | — | — |
| Urinary Tract InfectionInfections and infestations | 0/15 | 1/5 | — | — | — |
| costcochondritisMusculoskeletal and connective tissue disorders | 0/15 | 1/5 | — | — | — |
| HeadacheNervous system disorders | 3/15 | 1/5 | — | — | — |
| Chest DiscomfortRespiratory, thoracic and mediastinal disorders | 0/15 | 1/5 | — | — | — |
| PruritusSkin and subcutaneous tissue disorders | 2/15 | 1/5 | — | — | — |
participants who received at least one dose of RESP301 or HRZE
| Age, Continuous(years) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| Mean | 31.00 ± 10.09 | 31.20 ± 5.93 | — | — | — | 31.05 ± 9.08 |
| Sex: Female, Male(Participants) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | — | — | — | 3 |
| Male | 13 | 4 | — | — | — | 17 |
| Race (NIH/OMB)(Participants) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | — | — | 0 |
| Asian | 0 | 0 | — | — | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | — | 0 |
| Black or African American | 15 | 5 | — | — | — | 20 |
| White | 0 | 0 | — | — | — | 0 |
| More than one race | 0 | 0 | — | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | — | — | — | 0 |
| Weight(kg) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| Mean | 53.05 ± 9.83 | 50.08 ± 6.76 | — | — | — | 52.31 ± 8.85 |
| Height(m) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| Mean | 1.69 ± 0.07 | 1.65 ± 0.05 | — | — | — | 1.68 ± 0.07 |
| BMI(kg/m^2) | 1 (Active) | 2 (Control) | 3 (Active) | 4 (Active) | 5 (Active) | Total |
|---|---|---|---|---|---|---|
| Mean | 18.70 ± 3.58 | 18.34 ± 1.70 | — | — | — | 18.61 ± 3.17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD is confidential until the CSR is published
Ran from Sep 2023 to primary completion in Jul 2024, 9 months.
Results were first posted in Jul 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: RESP301 · Isoniazid · Rifampin · Pyrazinamide · Ethambutol
Thirty Respiratory Limited